logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
I

Immunotherapy

IF2.3
Papers112
Citations
Journal Papers 107
Publication Date
delete
Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer
deleteImmunotherapy
IF2.3
delete2026-10-10
delete0
PREAI
deleteRuoxi Xu; Pinchao Fan; Yiqiu Liu; Chengjun Zhu; Dandan Wang; Fang Yang; Xiaoxiang Guan
deleteShare
deleteSave
Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
deleteImmunotherapy
IF2.3
delete2026-10-09
delete0
PREAI
deleteSha Liu; Junjun Lu; Zhaojie Lyu; Zhengmao Lu; Yunmei Liu; Ruiying Zhang; Wentao Xu; Guoping Sun; Yingying Du; Lei Huang
deleteShare
deleteSave
Association of early dynamic changes in peripheral blood immune-inflammatory indices with subsequent acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a landmark analysis
deleteImmunotherapy
IF2.3
delete2026-10-08
delete0
PREAI
deleteLin Song; Wanghui Lv; Qingbo Wang; Yan Luo
deleteShare
deleteSave
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
deleteImmunotherapy
IF2.3
delete2026-10-08
delete0
PREAI
deleteYueqi Wang; Siqi Wang; Huijuan Fan; Wenjun Sun; Yanmei Fa; Yuxian Yang; Ronghua Chen; Kang Du; Shanshan Wu
deleteShare
deleteSave
Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia
deleteImmunotherapy
IF2.3
delete2026-10-08
delete0
PREAI
deleteXiaoyue Ren; Lijie Zhang; Linli Zhou; Shuqi Zhao
deleteShare
deleteSave
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
deleteImmunotherapy
IF2.3
delete2026-10-04
delete0
PREAI
deleteZhiwei Zheng; Lisheng Huang; Yuling Zhang; Huide Zhu; Ling Fang
deleteShare
deleteSave
Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States
deleteImmunotherapy
IF2.3
delete2026-10-04
delete0
deleteOAAI
deleteXiaohan Hu; Amin Haiderali; Yezhou Sun; Wilbur Pan
deleteShare
deleteSave
Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
deleteImmunotherapy
IF2.3
delete2026-10-01
delete0
PREAI
deleteCalogera Claudia Spagnolo; Irene Campo; Elena Fassi; Francesco Nucera; Paolo Ruggeri; Paola Muscolino; Carla Infurna; Antonio Ieni; Vanesa Gregorc; Chiara Lazzari; Mariacarmela Santarpia
deleteShare
deleteSave
Addressing socioeconomic barriers to immunotherapy access for non-small cell lung cancer in Japan
deleteImmunotherapy
IF2.3
delete2026-09-22
delete0
deleteOAAI
deleteHiroe Suzuki-Chiba; Atsushi Miyawaki
deleteShare
deleteSave
Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis
deleteImmunotherapy
IF2.3
delete2026-09-16
delete0
deleteOAAI
deleteAbdulrahman F. Al-Mashdali; Mujahid O. Abdelraof; Rasha Kaddoura; Azza M. Halfawi; Mohamed Elfatih M. Yousif; Mohammed Abdulgayoom; Abdul Rashid Shah; Shehab F. Mohamed
deleteShare
deleteSave
From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies
deleteImmunotherapy
IF2.3
delete2026-09-15
delete0
PREAI
deleteU Krishnaja; Neethu J; Maitheli Sarkar; Krishnakumar N. Menon; Bhargab Kalita
deleteShare
deleteSave
In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more
deleteImmunotherapy
IF2.3
delete2026-09-08
delete0
PREAI
deleteYulong Xia; Jintian Song; Jiong Wu
deleteShare
deleteSave
Bromodomain inhibitors in autoimmune diseases
deleteImmunotherapy
IF2.3
delete2026-09-06
delete0
PREAI
deleteMarcin Szczepanik; Wojciech Pociej; Joanna Kulpa; Jakub Senko; Oliwia Jerzyńska; Andrzej Pawlik
deleteShare
deleteSave
Cancer vaccines as targeted therapies: translational advances and challenges
deleteImmunotherapy
IF2.3
delete2026-09-05
delete0
PREAI
deleteZahra Shafaghat; Maryam Sadri; Mona Roozbehani; Fatemeh Kheiri; Maryam Dorfaki; Fatemeh Faraji
deleteShare
deleteSave
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma
deleteImmunotherapy
IF2.3
delete2026-09-02
delete0
PREAI
deleteCaner Kapar; Oğuzcan Özkan; Eda Eylemer Mocan; Sendag Yaslikaya; Ali Murat Tatlı; Goncagül Akdağ; Hacer Demir; Irem Bilgetekin; Kaan Helvacı; Fatih Selcukbiricik; Fatih Köse; Murat Sari; Gökmen Umut Erdem; Zehra Sucuoğlu İşleyen; Cagatay Arslan; Sinemis Celik; Türkkan Evrensel; Bekir Mert Durukan; Seher Nazli Kazaz; Banu Ozturk; Halil Çelik; Miraç Özen; Pınar Erel; Pervin Can Şancı; Yakup Ergün; Hakan Taban; Ömer Faruk Kuzu; Burcu Ulaş Kahya; Ahmet Melih Arslan; Abdullah Sakin; Murat Araz; Kerem Okutur; Fahri Akgül; Cem Mirili; Alper Sevinç; Fatih Atalah; Yakup Düzköprü; Burcu Gülbağcı; Nurten Kandemir; Hakan Kosku; Esra Aydın; Dilek Erdem; Murad Guliyev; Mesut Yılmaz; Yaşar Çulha; Berksoy Şahin; Pınar Gürsoy; Mustafa Erman; Yüksel Ürün; Deniz Tural
deleteShare
deleteSave
Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1–negative cancers: a systematic review and meta-analysis
deleteImmunotherapy
IF2.3
delete2026-08-25
delete0
PREAI
deleteSusu Zhou; Vishw Patel; Noriko Kishi; Komal Akhtar; Che-Kai Tsao
deleteShare
deleteSave
Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report
deleteImmunotherapy
IF2.3
delete2026-08-25
delete0
PREAI
deleteZhiqiang Li; Yufei Li; Yuhan Zhang; Qiuxia Ye; Jing He; Mingwei Li
deleteShare
deleteSave
Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer
deleteImmunotherapy
IF2.3
delete2026-08-24
delete0
PREAI
deleteAlfredo Tartarone; Raffaele Conca; Alessandra Perrone; Rosa Lerose
deleteShare
deleteSave
Injection-based safety of aqueous venom immunotherapy during venom extract shortage: impact of forced depot-to-aqueous switching
deleteImmunotherapy
IF2.3
delete2026-08-24
delete0
PREAI
deleteGökten Bulut; Rukiye Demiralp; Şefika Karabaş; Fidan Coşkun
deleteShare
deleteSave
Neoantigen in cancer immunotherapy: mechanism, therapeutic strategies and future perspectives
deleteImmunotherapy
IF2.3
delete2026-08-22
delete0
PREAI
deleteAditya Raj; Zuber Khan; Mumtaz; Sidharth Mehan; Tapan Lamba; Niyati Pandoh; Keerti Dayal
deleteShare
deleteSave